AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Growth_hormone

    Follistatin-344 (1mg)

    SubcutaneousDaily (loading) / Every 2nd Day (maintenance)1mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    Research peptide — Myostatin antagonist. Not clinically approved.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Research-only — no FDA/EMA approval
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Free Access

    How It Works

    Follistatin-344 is a monomeric, cysteine-rich glycoprotein belonging to the follistatin family. It functions as a natural antagonist of members of the TGF-β superfamily, primarily myostatin (GDF-8) and activins. Myostatin is the main negative regulator of skeletal muscle growth — when follistatin binds to myostatin, it blocks its interaction with ActRIIB receptors, thereby lifting the brake on muscle hypertrophy. The 344 isoform is the longest sequence (344 amino acids) with a broader binding spectrum compared to the 288 and 315 isoforms. In experimental mouse models, follistatin administration increased muscle mass by 15–20% within 4 weeks, while in non-human primates, significant increases in skeletal muscle mass were observed without a change in muscle fiber type.

    Quick Start

    • Reconstitution: Add 1.0 mL of bacteriostatic water → 1 mg/mL (1000 mcg/mL).
    • Loading: 100 mcg/day × 10 days · Maintenance: 100 mcg every 2nd day × 20 days.
    • Storage: Lyophilized: −20 °C · after reconstitution: refrigerate 2–8 °C · use within 14–21 days.
    Detailed Protocol Data

    Loading + Maintenance (1 mL = 1 mg/mL)

    Educational only
    Vial Size— affects syringe units
    BAC Water1 mL
    Concentration1.00 mg/mL

    Route: Subcutaneous | Frequency: Daily (loading) / Every 2nd Day (maintenance)

    WeekDoseUnits (per injection)
    Days 1–10 (Loading)
    100 mcg (0.1 mg)
    10 Units (0.10 mL)
    Days 11–30 (Maintenance)
    100 mcg (0.1 mg)
    10 Units (0.10 mL)

    Loading: once daily subcutaneously for 10 days. Maintenance: every 2nd day (EOD) for the next 20 days. Total cycle: 30 days.

    Related compounds

    Reconstitution Steps

    1. Withdraw 1.0 mL of bacteriostatic water with a sterile syringe.
    2. Inject slowly down the side of the vial; do not spray directly onto the powder.
    3. Gently swirl until fully dissolved — do not shake (the protein is delicate).
    4. Note the date and concentration (1 mg/mL); refrigerate at 2–8 °C.
    5. Use within 14–21 days after reconstitution.

    Protocol Overview

    • Objective: Inhibit myostatin (GDF-8) and activins to support skeletal muscle growth.
    • Schedule: 30-day cycle: 10 days loading (daily) + 20 days maintenance (EOD).
    • Dose: 100 mcg per injection (loading & maintenance).
    • Cycling: 30 days on, 4–8 weeks off.

    Dosing Protocol

    • Loading Phase (Days 1–10): 100 mcg daily subcutaneously to saturate levels.
    • Maintenance (Days 11–30): 100 mcg every 2nd day (EOD) to maintain myostatin inhibition.
    • Timing: Morning or post-workout.
    • Cycle Duration: 30 days; pause 4–8 weeks before repeating.
    • Break between cycles: After the cycle (30 days), a 4–8 week break is recommended before repeating.

    Washout & Cycle Restart

    When can I restart?

    After the cycle (30 days), a 4–8 week break is recommended before repeating.

    Minimum wait period: 6 weeks

    Storage Instructions

    • Lyophilized: Store at −20 °C in dry, dark conditions; stable for up to 24 months.
    • Reconstituted: Refrigerate at 2–8 °C; use within 14–21 days.
    • Avoid freeze-thaw cycles; the protein is highly sensitive to temperature changes.

    Important Notes

    • Follistatin-344 is a protein, not a peptide — especially sensitive to temperature and mechanical stress.
    • Do not shake — risk of denaturation.
    • Research compound — no approved human clinical trials for dosing exist.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Myostatin inhibition — removal of the main negative regulator of muscle growth.
    • Increased skeletal muscle mass in experimental models (mice, primates).
    • Broad binding spectrum of TGF-β members (myostatin, activins A/B).
    • Does not alter the composition of muscle fiber types (type I & II).

    Potential Side Effects:

    • Limited human clinical data — side effects are not fully documented.
    • Potential mild injection site reactions (redness, tenderness).
    • Theoretical concern: effects on reproductive function due to activin inhibition (FSH regulation).
    • Theoretical concern: long-term effects on potential organ fibrosis (myostatin also regulates cardiac muscle).

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🎗️ Cancer Markers
    🔴 High Risk

    Activin inhibition — theoretical oncogenesis risk

    Follistatin-344 inhibits activin and myostatin. Activin has tumor-suppressive roles in certain tissues. Its inhibition could theoretically promote growth of pre-existing tumors.

    📄 Mol Cell Endocrinol, 2004
    🧬 Endocrine
    🔴 High Risk

    FSH suppression — reproductive dysfunction

    Follistatin suppresses FSH via activin binding. May cause infertility, menstrual irregularities, or reduced spermatogenesis.

    📄 Endocrine Reviews, 2001

    References

    1. Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth (PMC) — Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
      View Source
    2. Follistatin Gene Delivery Enhances Muscle Growth in Nonhuman Primates — Follistatin gene delivery enhances muscle growth and strength in nonhuman primates
      View Source
    3. Myostatin Signal Transduction: Biology and Therapeutic Potential — Myostatin signal transduction: biology and therapeutic potential
      View Source
    4. Myostatin Inhibition in Muscle Disease — Nature Reviews Drug Discovery — Myostatin inhibition in muscle disease: progress and challenges
      View Source
    5. Follistatin: A Multifunctional Regulatory Protein — Follistatin: a multifunctional regulatory protein
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Research-only
    FDA Status
    0
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    Research peptide — No regulatory approval from any agency

    Research peptide — Myostatin antagonist. Not clinically approved.

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu